Niki Biosolutions (NIKI) revenue and earnings history
Niki Biosolutions's annual figures for 8 fiscal years, as filed with the SEC.
Over 2 years, from fiscal 2021 to fiscal 2023, revenue grew at a compound rate of −47.1% a year.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | — | −$1.36M | −$1.84M | — | — | — | — | — | $3.45M | — | 20-F |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Niki Biosolutions (NIKI) on OQRO.
Common questions
How fast has Niki Biosolutions's revenue grown?
From $1.54M in fiscal 2021 to $431K in fiscal 2023: a compound annual growth rate of −47.1% over 2 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Niki Biosolutions been profitable?
It reported a net loss in 7 of the years shown (2018, 2019, 2021, 2022, 2023, 2024, 2025). The highest net income was $4.92M in fiscal 2020.
Does Niki Biosolutions buy back shares or pay dividends?
None of the 8 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Niki Biosolutions tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.